INTRODUCTION: Even as substantial improvements have been made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than 20 years ago, there is still a considerable unmet need in patients with HER2-expressing breast cancer (BC) and other solid tumors. Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate approved for the treatment of metastatic breast cancer (BC) and gastric cancer (GC) and is under active investigation in other solid tumors, including non-small cell lung cancer, colorectal cancer, and HER2-low-expressing tumors.AREAS COVERED: The current treatment and investigational landscape of HER2-positive and HER2-low metastatic BC (mBC) and the preclinical and clinical trials investigating T-DXd. To identify relevant literature, a search was performed on English-language publications and congress abstracts.EXPERT OPINION: T-DXd is likely to become the standard of care for second-line treatment of HER2-positive mBC, and it may play a role in the treatment of hormone receptor-positive and triple-negative mBC with HER2-low expression. Because it was recently approved in the United States and Japan to treat HER2-positive metastatic GC, it holds promise for the treatment of other HER2-positive solid tumors, including colorectal cancer, non-small cell lung cancer, and HER2-low-expressing BC.

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond / J. Perez, L. Garrigós, M. Gion, P.A. Jänne, K. Shitara, S. Siena, J. Cortés. - In: EXPERT OPINION ON BIOLOGICAL THERAPY. - ISSN 1471-2598. - (2021 Apr 01). [Epub ahead of print]

Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond

S. Siena;
2021

Abstract

INTRODUCTION: Even as substantial improvements have been made in human epidermal growth factor receptor 2 (HER2)-targeted therapies since the approval of trastuzumab more than 20 years ago, there is still a considerable unmet need in patients with HER2-expressing breast cancer (BC) and other solid tumors. Trastuzumab deruxtecan (T-DXd) is a newer antibody-drug conjugate approved for the treatment of metastatic breast cancer (BC) and gastric cancer (GC) and is under active investigation in other solid tumors, including non-small cell lung cancer, colorectal cancer, and HER2-low-expressing tumors.AREAS COVERED: The current treatment and investigational landscape of HER2-positive and HER2-low metastatic BC (mBC) and the preclinical and clinical trials investigating T-DXd. To identify relevant literature, a search was performed on English-language publications and congress abstracts.EXPERT OPINION: T-DXd is likely to become the standard of care for second-line treatment of HER2-positive mBC, and it may play a role in the treatment of hormone receptor-positive and triple-negative mBC with HER2-low expression. Because it was recently approved in the United States and Japan to treat HER2-positive metastatic GC, it holds promise for the treatment of other HER2-positive solid tumors, including colorectal cancer, non-small cell lung cancer, and HER2-low-expressing BC.
Antibody-drug conjugate; DS8201; HER2 targeted; HER2-positive; T-DXd; breast cancer; colorectal cancer; gastric cancer; non–small cell lung cancer; trastuzumab deruxtecan
Settore MED/06 - Oncologia Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
Trastuzumab deruxtecan in HER2 positive metastatic breast cancer and beyond.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 903.86 kB
Formato Adobe PDF
903.86 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/829151
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact